Fig. 3
Longitudinal cfKRASmut and CA 19–9 monitoring. a Top left: Absolut levels of cfKRASmut during observation period. Patients with relapse during study period are marked red. Black arrow mark the time of disease recurrence. Top right: Relapse versus non-relapse patients with increase in cfKRASmut during observation period. Fisher’s exact test was used to test for statistical significance between the two groups. P values < 0.05 were considered significant. Bottom left: Absolut levels of CA 19–9 during observation period. Patients with relapse are marked red. Black arrows mark the time of disease recurrence. Bottom right: Relapse versus non-relapse patients with increase in cfKRASmut during observation period. Fisher’s exact test was used to test for statistical significance between the two groups. P values < 0.05 were considered significant. b Swimmers plot of disease course of resected PDAC patients. cfKRASmut and CA 19–9 analysis in blood were compared to clinical course of disease before and during adjuvant chemotherapy. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease